Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02771730 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
A Phase 1 study, sponsored by Emergent BioSolutions.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02771730: Clinical Trial Phase 1 study, sponsored by Emergent BioSolutions.
NCT02771730 is a Phase 1 study that was terminated before completion, run by Emergent BioSolutions. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02771730, a Phase 1 study, was terminated before completion, sponsored by Emergent BioSolutions.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus vector. The adenovirus vector may help the vaccines stimulate an immune response. Researchers want to see how the immune system will respond to these vaccines as well as if they are safe to give to people. Participants cannot get HIV from these vaccines. However, researchers also want to see if the vaccine's adenovirus is contagious. Adenoviruses cause cold symptoms or mild eye infections, therefore household and intimate contacts will be asked to participate as well.
Primary Outcome
To evaluate vaccine tolerability in terms of local and systemic reactogenicity signs and symptoms, laboratory measures of safety, and AEs and SAEs.
Interventions
- OTHER Placebo Comparator
- BIOLOGICAL Ad4-mgag
- BIOLOGICAL Ad4-EnvC150
- BIOLOGICAL AIDSVAX B/E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Why NCT02771730 stopped before completion
NCT02771730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo Comparator is the first listed.
NCT02771730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02771730 about?
NCT02771730 is a clinical study titled "Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults". The purpose of this study is to test experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus vector. The adenovirus vector may help the vaccines stimulate an immune response. Researchers want to see how the immune system will respond to these vaccines as well as if they are s...
What is the current status of trial NCT02771730?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-03. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02771730?
The interventions under investigation include: Placebo Comparator (OTHER), Ad4-mgag (BIOLOGICAL), Ad4-EnvC150 (BIOLOGICAL), AIDSVAX B/E (BIOLOGICAL).
Who is sponsoring clinical trial NCT02771730?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02771730's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia